TransMedics Earnings Call Highlights Record Growth

TransMedics (TMDX) reported Q3 2026 revenue of $203M, up 41% YoY, with strong growth in liver and heart transplants. Revenue guidance raised to $764M-$774M. Margins improved excluding PAD Aviation. International expansion and clinical studies progress noted.

Original reporting
Published Nov 15, 2026, 2:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 7:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$TMDX
Neutral
medium confidence
Mentioned
$TMDX
Relevance
4/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$TMDXNeutralLow
01

Why it matters

No new catalyst; the market has likely already incorporated the earnings surprise.

02

Market read

Recap of already‑public earnings; minimal immediate trading relevance.

03

What to watch

Potential regulatory timing and donor shortages could curb future growth.

Relevance 4/10Novelty 2/10Timing: none (post‑earnings recap)

Background

The article repeats figures from the Q3 2026 earnings release that occurred ten days earlier.

Company-level read

Ticker impact

$TMDXNeutralMedium confidence
Context

Recaps Q3 2026 earnings with record revenue and case volume, and raises full-year guidance.

Expected impact

modest upside pressure as investors reaffirm growth outlook

Evidence & confidence

All numbers were disclosed in the prior earnings release; the article adds no fresh data.

Market effects

Highlights continued growth in organ‑preservation technology, but no immediate sector shift.

International revenue growth noted, yet still a small share of total sales.

Limited; the story is company‑specific and already priced.

Counterpoint

With margins pressured by service mix, the rally may be overstated.

Key entities

  • TransMedics Group

    Medical device firm specializing in organ preservation platforms.

Related articles

Med

TransMedics revenue up 41% to USD 203M in Q3 2026

TransMedics reported Q3 2026 revenue of $203M, up 41% YoY, driven by increased organ transplant volumes and logistics services. Gross margin was 58.5%, with operating income of $28.1M. The company cited growth catalysts like ENHANCE Heart Part B and DENOVO Lung, and plans for European expansion. Net income fell to $17.1M, or $0.46 per share, from $24.3M, or $0.66 per share, a year earlier.

$TMDXMed

TransMedics Group Q3 Earnings Call Highlights

TransMedics Group reported Q3 product gross margin at 79.2% and service gross margin at 32.2%. Adjusted net income was $18.9M, or $0.51 per share, with $493M in cash. The company completed ENHANCE Heart Part A enrollment and plans submissions in 2027. It also targets European expansion and kidney platform trials in 2027, maintaining its full-year adjusted operating margin outlook of 12.5% to 14%.